This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Analgesic Treatment Mediated by Arcoxia (0663-093)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00380523
First received: September 22, 2006
Last updated: March 16, 2015
Last verified: March 2015
September 22, 2006
March 16, 2015
April 2005
May 2005   (Final data collection date for primary outcome measure)
Evaluate pain using the verbal analog scale (evaluate pain before starting treatment and then evaluate pain every day after had taken arcoxia up to three days)
Same as current
Complete list of historical versions of study NCT00380523 on ClinicalTrials.gov Archive Site
  • Patient satisfaction with the drug therapy using PGART scale
  • Patient satisfaction was obtained at the end of treatment(on third day)
Same as current
Not Provided
Not Provided
 
Analgesic Treatment Mediated by Arcoxia (0663-093)
Analgesic Treatment Mediated by Arcoxia
Allow physicians to test the efficacy of arcoxia in patients with acute pain.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pain
Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
237
May 2005
May 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of acute pain susceptible of pharmacological treatment
  • Greater than 18 years of age
  • Voluntary acceptance to participate in the study and signature of the informed consent form

Exclusion Criteria:

  • Allergy to etoricoxib or any of its components
  • Less than 18 years old
  • Patient is taking anticoagulants
  • Patient that already has taken any drug as analgesic
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00380523
0663-093
2006_034
Not Provided
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP